In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
about
Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirA mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirAn assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cellsStrain-specific viral distribution and neuropathology of feline immunodeficiency virusModel system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coliGenotypic testing for human immunodeficiency virus type 1 drug resistance.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesEfficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patientsNelfinavir mesylate.Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precurIn vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.New anti-HIV agents and targets.Simplified regimens for treating HIV infection and AIDS.Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenAtazanavir: new option for treatment of HIV infection.A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.Atazanavir: improving the HIV protease inhibitor class.Atazanavir for the treatment of human immunodeficiency virus infection.A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.Atazanavir: the advent of a new generation of more convenient protease inhibitors.Review of atazanavir: a novel HIV protease inhibitor.Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.Review of tipranavir in the treatment of drug-resistant HIV.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Atazanavir: simplicity and convenience in different scenarios.Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavirGRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.Atazanavir: its role in HIV treatmentSimplification strategies to reduce antiretroviral drug exposure: progress and prospects.Atazanavir: in pediatric patients with HIV-1 infection.Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nActivities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir.Quantitative determination of free/bound atazanavir via high-throughput equilibrium dialysis and LC-MS/MS, and the application in ex vivo samples.
P2860
Q24801797-8DB3CA00-000B-4853-9147-B31C6F06A268Q27645052-4DB638E3-F9AD-459F-8DF4-CF961647A100Q28344112-2C4744A1-6C75-4E5C-8F64-063526BAE70DQ28474218-DD84C9F0-4CA8-44E7-99B0-928D93345DDBQ30462523-EB0060EA-0CF6-4901-95F6-B8842A9E85F2Q33204167-8CBEC076-E1A4-4375-9A8F-B47EF5BC5FD5Q33906239-E64C5F13-0749-4314-B7F1-1399001D50A5Q33935276-B24D28B4-48FE-485E-A4EA-15E113A420E2Q34005107-D4386519-5B25-4248-A5A0-58689C1228D5Q34141845-F0320319-57CC-4024-B8A1-BFF58F5912CAQ34181862-559E4CDB-96EB-4F50-A919-36CB39E3B822Q34344036-00DE6563-0018-4704-85B2-9C941BFD1278Q34529347-09B6E8F9-7B2F-422B-BC25-6C8A0FBDB4D6Q34757951-C17AB5B4-7455-4F8E-80C5-2F87BB499E6EQ34944447-39111082-1E7E-4D42-ABD1-AE090C9D8C79Q35203402-F3144E0A-69C3-4F8C-9153-E0AFE049A33DQ35758844-26869975-1387-4990-B840-41A945622544Q35779915-803696C7-319D-4311-831A-646AF9568155Q35840811-E88F941F-9307-47B5-934F-AF036754C4C2Q35917234-C0A136E2-ECBA-4768-9878-0A21484D1BDEQ35976835-43956EBF-D92D-4ED6-9E10-2D21D1E944BBQ35978823-DE469DAC-89AA-4461-9226-9244F0722737Q35992805-B89C6F4A-28F7-46EF-B787-7A7EC727B891Q36047851-63007689-F55C-4716-A5C2-069B2AF84B1DQ36070100-CD602D22-1BBF-4843-9243-B817D7CC9EA7Q36222006-16214F29-A46B-4321-A68D-7762DF9521C3Q36506829-B6837605-1E62-42AE-9CA7-1E79AEA7D052Q36538695-610EE2BA-05E8-4452-951B-6F9AF67B7B07Q36642990-71111313-2802-423F-AF05-970C46DD500EQ36723853-CDA80A4D-207C-45DD-9299-15003C7B3392Q36765802-F8468596-3584-4B47-86AF-76CC114EBCA2Q36841895-69141807-23F0-40B1-BB55-E0D57F79DC1CQ37115695-32AD9345-39A4-437D-915B-9A342A5B0941Q37249418-B85D4E99-36A6-47C0-8689-2334667CEB40Q37277829-4BB77C0E-2913-4D33-877D-E7C64E052366Q37980179-CF882B21-058D-435D-B348-60E688A77D13Q39653073-0302C04E-0A73-4B5D-90BE-5AE09584DDD1Q39743483-67DF6A7B-A8B9-4EBC-8BA5-B40AC56305BDQ40117949-25AD6FB3-834E-46EA-9F34-F235B03A2051Q41588370-15197F13-8C5D-4924-845D-6926153B7BB1
P2860
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro resistance profile of ...... protease inhibitor BMS-232632
@ast
In vitro resistance profile of ...... protease inhibitor BMS-232632
@en
In vitro resistance profile of ...... protease inhibitor BMS-232632
@nl
type
label
In vitro resistance profile of ...... protease inhibitor BMS-232632
@ast
In vitro resistance profile of ...... protease inhibitor BMS-232632
@en
In vitro resistance profile of ...... protease inhibitor BMS-232632
@nl
prefLabel
In vitro resistance profile of ...... protease inhibitor BMS-232632
@ast
In vitro resistance profile of ...... protease inhibitor BMS-232632
@en
In vitro resistance profile of ...... protease inhibitor BMS-232632
@nl
P2093
P2860
P3181
P1476
In vitro resistance profile of ...... protease inhibitor BMS-232632
@en
P2093
B S Robinson
R J Colonno
T P Spicer
P2860
P304
P3181
P356
10.1128/AAC.44.9.2319-2326.2000
P407
P577
2000-09-01T00:00:00Z